On Dec. 15, 2020, AXIM Biotechnologies announced the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based diagnostic test for the detection of SARS-CoV-2 neutralizing antibodies. This application marked AXIM’s fourth COVID-19 neutralizing antibody-focused patent application.